Aibo Medical: Plans to Acquire 68.31% Equity of Demai Medical for 683 million yuan.

Ai Bo Medical announced that it plans to use a combination of merger and acquisition loans and its own funds of 683 million yuan to acquire 68.31% equity of DeMei Medical. After the company pays the first installment of the stock transfer payment, all the equity of DeMei Medical involved in this transaction will be completed for industrial and commercial change registration. The company will enjoy all the rights and interests as a shareholder of the target company, and DeMei Medical will become a subsidiary of the company and be included in the company's consolidated financial statements. As the leading enterprise in domestic sports medicine, the target company is a national high-tech enterprise and a national-level specialized and new "little giant" enterprise, with 276 patented technologies, a modern production base and research and development center, and technical research and development capabilities and market competitiveness. The target company has been selected as part of the fourth batch of national high-value medical consumables group A procurement, ranking at the forefront of the industry; it has rich clinical expert resources, and its sales network covers the whole country as well as overseas regions such as Southeast Asia, Latin America, the Middle East, and Europe. There is a certain degree of synergy between the company and the target company in areas such as product/technology research and development, manufacturing, domestic and overseas sales channels.